Published in:
Open Access 01-02-2019 | Original Research
Incidence of Diabetes in the Working Population in Spain: Results from the ICARIA Cohort
Published in: Diabetes Therapy | Issue 1/2019
Login to get accessAbstract
Introduction
Our objective was to evaluate the incidence of type 2 diabetes mellitus (T2DM) in a working population in Spain and to assess associations between its development and several risk factors.
Methods
The ICARIA (Ibermutuamur CArdiovascular RIsk Assessment) cohort (n = 627,523) includes ~3% of Spanish workers. This analysis was undertaken in individuals whose glycaemic status during the index period (May 2004–December 2007) was determined to be normal or indicative of prediabetes [fasting plasma glucose (FPG) 100–125 mg/dl] and who had at least one FPG measurement taken 9 months after a first measurement during follow-up (May 2004–June 2014) (n = 380,366). T2DM patients were defined as those with an FPG ≥ 126 mg/day and those who had already been diagnosed with T2DM or were taking antihyperglycaemic medications.
Results
The incidence rate of T2DM was 5.0 [95% confidence interval (CI) 4.9–5.1] cases per 1000 person-years. Under multivariate logistic regression analysis, the factor showing the strongest association with the occurrence of T2DM was the baseline FPG level, with the likelihood of T2DM almost doubling for every 5 mg/dl increase in baseline FPG between 100 and < 126 mg/dl. The presence of other cardiometabolic risk factors and being a blue-collar worker were also significantly associated with the occurrence of T2DM.
Conclusions
The incidence of T2DM in the working population was within the range encountered in the general population and prediabetes was found to be the strongest risk factor for the development of diabetes. The workplace is an appropriate and feasible setting for the assessment of easily measurable risk factors, such as the presence of prediabetes and other cardiometabolic factors, to facilitate the early detection of individuals at higher risk of diabetes and the implementation of diabetes prevention programmes.
Funding
Eli Lilly and Co.